Fatty liver and nonalcoholic steatohepatitis: Where do we stand and where are we going?

Digestive Diseases

Volumn 17, Issue 2, 1999, Pages 80-89

  Lonardo, Amedeo ^a,b  

^a Modena City Hospital   (Italy)

^b Ospedale Civile   (Italy)

Author keywords

Atherosclerosis; Cancer; Diagnosis; Epidemiology; Fatty liver; Metabolic syndrome; Natural history; Nonalcoholic steatohepatitis; Pathogenesis; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLINE; POLYMYXIN; URSODEOXYCHOLIC ACID;

DIET THERAPY; ECHOGRAPHY; FATTY LIVER; HEPATITIS; HEPATITIS C VIRUS; HUMAN; IRON METABOLISM; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; MEDICAL INFORMATION; PRIORITY JOURNAL; REVIEW;

FATTY LIVER; HEPATITIS; HEPATITIS C; HUMANS; INSULIN RESISTANCE; SYNDROME;

EID: 0032828612     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016909     Document Type: Review

References (119)

1. Spiro HM: Primarily structural disorders; in Spiro HM (ed): Clinical Gastroenterology. New York, McGraw-Hill, 1993, pp 1059-1108.
2. Theal RM, Scott K: Evaluating asymptomatic patients with abnormal liver function test results. Am Family Physician 1996;53:2111-2119.
3. Lieverse RJ, Jansen JBMJ, Masclee AAM, Lamers CBHW: Gastrointestinal disturbances with obesity. Scand J Gastroenterol 1993; 28(suppl 200):53-58.
4. Ikai E, Honda R, Yamada Y: Serum gamma-glutamyl transpeptidase level and blood pressure in nondrinkers: A possible pathogenetic role of fatty liver in obesity-related hypertension. J Hum Hypertens 1994;8:95-100.
5. Wannamethee G, Ebrahim S, Shaper AG: Gamma-glutamyltransferase: Determinants and associations with mortality from ischaemic heart disease and all causes. Am J Epidemiol 1995;142:699-708.
6. Perry IJ, Wannamethee SG, Shaper AG: Prospective study of serum γ-glutamyltransferase and risk of NIDDM. Diabetes Care 1998;21: 732-737.
7. Conjeevaram HS, Everhart JE, Hoofnagle JH: Predictors of a sustained beneficial response to interferon-alpha therapy in chronic hepatitis C. Hepatology 1995;22:1326-1329.
8. Todo S, Demetris AJ, Makowka L, Teperman L, Podesta L, Shaver T, Tzakis A, Starzl TE: Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989;47:903-905.
9. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-145.
10. Thaler H: Relation of steatosis to cirrhosis. Clin Gastroenterol 1975;4:273-280.
11. Causse X, Gargot D, Michenet P: Stéatoses hépatiques. Primiére partie: stéatoses macrovésiculaires. Gastroentérol Clin Biol 1995;19:58-65.
12. Causse X, Gargot D, Michenet P: Stéatoses hépatiques. Deuxième partie: stéatoses microvésiculaires. Gastroentérol Clin Biol 1995;19: 66-75.
13. Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis. Med Clin North Am 1996; 80:1147-1166.
14. Lonardo A: La sindrome del fegato iperecogeno. E'la steatosi epatica una components della sindrome metabolica da insulinoresistenza? Argom Gastroenterol Clin 1997;10:77-89.
15. Ludwig J, McGill DB, Lindor KD: Review: Nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997;13:398-403.
16. O'Connor BJ, Katbamna B, Tavill AS: Nonalcoholic fatty liver (NASH syndrome). Gastroenterologist 1997;5:316-329.
17. Day CP, James OFW: Steatohepatitis: A tale of two 'hits'? Gastroenterology 1998;114:842-845.
18. Day CP, James OFW: Non-alcoholic steatohepatitis (NASH): Innocent bystander or guilty party? J Hepatol 1998;27:1463-1466.
19. James OFW, Day CP: Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance. J Hepatol 1998;29: 495-501.
20. Taylor KJW: Grey scale ultrasound imaging: The anatomy and pathology of the liver. Radiology 1976;119:415-423.
21. Debongnie JC, Pauls C, Fievez M, Wibin E: Prospective evaluation of the diagnostic accuracy of liver ultrasonography. Gut 1981;22:130-135.
22. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtusuki M: Ultrasonographical diagnosis of fatty liver: Significance of the liver-kidney contrast. Tohoku J Exp Med 1983;139:43-50.
23. Bolondi L, Labò G, Gandolfi L: The liver; in Bolondi L, Labò G, Gandolfi L (eds): Diagnostic Ultrasound in Gastroenterology. Instrumentation. Clinical Problems and Atlas. Padova. Piccin/Butlerworths, 1984, pp 87-175.
24. Saverymuttu SH, Joseph AEA, Maxwell JD: Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986;292:13-15.
25. Weill FS: Hepatomegaly and diffuse disease; in Weill FS (ed): Ultrasound Diagnosis of Digestive Diseases. Berlin, Springer, 1990, pp 107-120.
26. Joseph AEA, Saverymuttu SH, Al-Salam S, Cook MG, Maxwell JD: Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26-31.
27. Lonardo A, Bellini M, Tondelli E, Frazzoni M, Grisendi A, Pulvirenti M, Della Casa G: Nonalcoholic steatohepatitis and the 'bright liver syndrome': Should a recently expanded clinical entity be further expanded? Am J Gastroenterol 1995;90:2072-2074.
28. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M: Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-149.
29. Lu SN, Wang LY, Su WP, Chen SC, Chuang WL, Hsieh MY, Chang WY, Chen JC: Prevalences of asymptomatic monographic findings. J Ultrasound Med ROC 1989;6:173-177.
30. Oshibuchi M, Nishi F, Sato M, Ohtake H, Okuda K: Frequency of abnormalities detected by abdominal ultrasound among Japanese adults. J Gastroenterol Hepatol 1991;6:165-168.
31. Kawai N, Kawai T, Kawai K: Ultrasonic and laboratory studies on fatty liver in white-collar workers. Nippon Shokakibyo Gakkai Zasshi 1995;92:1058-1065.
32. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y: Association between hepatic steatosis, insulin resistance and hyperinsulinemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995;9:101-105.
33. Brogna A, Bucceri AM, Ferrara R, Di Martino M, Maina M, Catalano F, Blasi A: Prevalence of diffuse fatty infiltration of the liver in a population having abdominal ultrasonography. Ital J Gastroenterol 1997;29(suppl 2):A169.
34. Lonardo A, Bellini M, Tartoni P, Tondelli E: The bright liver syndrome. Prevalence and determinants of a 'bright' liver echopattern. Ital J Gastroenterol Hepatol 1997;29:351-356.
35. el-Hassan AY, Ibrahim EM, al-Mulhim FA, Nabhan AA, Chammas MY: Fatty infiltration of the liver: Analysis of prevalence, radiological clinical features and influence on patient management. Br J Radiol 1992;65:774-778.
36. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;12: 1106-1110.
37. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, Kusano Y: Prevalence of fatty liver in Japanese children and relation to obesity. Anepidemiological ultrasonographic survey. Dig Dis Sci 1995;40:2002-2009.
38. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen IE, Lefebvre PJ: Liver abnormalities in severely obese subjects: Effects of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-226.
39. Tessitore L, Sesca E, Greco M, Pani P, Dianzani MU: Sexually differentiated response to choline in choline deficiency and ethionine intoxication. Int J Exp Pathol 1995;76:125-129.
40. Van Steenbergen W, Lanckmans S: Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord 1995;19(suppl 3):27-36.
41. Cotrozzi G, Casini Raggi V, Relli P, Buzzelli G: Ruolo del fegato nella regolazione del metabolismo glucidico in corso di diabete e di epatopatia cronica. Ann Ital Med Int 1997;12:5-12.
42. Huth VK, Burkard M, Goebel T: Dyslipoproteinämie und Diabetes mellitus heim metabolischen Syndrom. Fortschr Med 1992;110:200-204.
43. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, Rubino A: Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428-1432.
44. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, Cristianini G, and the Dionysos Study Group: Prevalence of chronic liver disease in the general population of northern Italy: The Dionysos Study. Hepatology 1994;20:1442-1449.
45. Hsieh SD, Yoshinaga H: Is there any difference in coronary heart disease risk factors and prevalence of fatty liver in subjects with normal body mass index having different physiques? Tohoku J Exp Med 1995;177:223-231.
46. Kral JG, Schaffner F, Pierson RN Jr, Wang J: Body fat topography as an independent predictor of fatty liver. Metabolism 1993;42:548-551.
47. Tucikowski T, Milewski B, Dzieniszewski J, Rakoczy A, Klosiewicz-Latoszek L: Liver steatosis assessed by ultrasonographic examination in patients with hyperlipoproteinemia (in Polish). Wiad Lek 1994;47:725-730.
48. Umeki S, Hisamoto N, Hara Y: Study on background factors associated with impaired glucose tolerance and/or diabetes mellitus. Acta Endocrinol 1989;120:729-734.
49. Falchuk KR, Conlin D: The intestinal and liver complications of diabetes mellitus. Adv Intern Med 1993;38:269-286.
50. Maher JJ: Alcoholic Liver Disease: in Feldman M, Scharschmidt BF, Sleisenger MH (eds): Sleisenger and Fordtran's Gastrointestinal and Liver Disease, ed 6. Philadelphia, Saunders, 1998, pp 1199-1214.
51. Derr RF, Porta EA, Larkin EC, Rao GA: Is ethanol per se hepatotoxic? J Hepatol 1990;10: 381-386.
52. Iturriaga H, Bunout D, Hirsch S, Ugarte G: Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr 1988;47:235-238.
53. Bellentani S, Saccoccio G, Sodde M, Fratti N, De Martin C, Tiribelli C, Manenti F, and the Dionysos Study Group: Is alcohol abuse the main cause of fatty liver? Results from Dionysos study: A cohort study on an open population. Ital J Gastroenterol 1994;26:52:19.
54. Bellentani S, Saccoccio G, Masutti F, Croce L, Tiribelli C: Obesity and not alcohol intake is the main cause of liver steatosis. J Hepatol 1998; 28(suppl 1):129.
55. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC: Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25: 108-111.
56. Hodgson M, Van Thiel DH, Goodman-Klien B: Obesity and hepatotoxins as risk factors for fatty liver disease. Br J Ind Med 1991;48:690-695.
57. Redlich CA, Cullen MR: Nonalcoholic steatohepatitis. Ann Intern Med 1997;127:410.
58. Uchino T, Endo F, Ikeda S, Shiraki K, Sera Y, Matsuda I: Three brothers with progressive hepatic dysfunction and severe hepatic steatosis due to a patent ductus venosus. Gastroenterology 1996;110:1964-1968.
59. Okolo P III, Diehl AM: Nonalcoholic steatohepatitis and focal fatty liver: in Feldman M, Scharschmidt BF, Sleisenger MH (eds): Sleisenger and Fordtran's Gastrointestinal and Liver Disease, ed 6. Philadelphia, Saunders, 1998, pp 1215-1220.
60. Bacon BR, Farahvash J, Janey CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103-1109.
61. Lonardo A, Bellini M, Frazzoni M, Lonardo F, Tondelli E, Grisendi A, Pulvirenti M, Della Casa G, Melini L: Doses the 'bright liver syndrome' exist? Endoscopy 1995;27(suppl 3):A61.
62. Lonardo A: Is nonalcoholic steatohepatitis another facet of the bright liver syndrome? Ital J Gastroenterol 1996;28:187.
63. Tarugi P, Lonardo A, Ballarini G, Grisendi A, Pulvirenti M, Bagni A, Calandra S: Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. Gastroenterology 1996;111:1125-1133.
64. Lonardo A, Tarugi P, Ballarini G, Bagni A: Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy and hepatocellular carcinoma. A Case report. Dig Dis Sci 1998;43:2489-2492.
65. Bach N, Tilling SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology 1992;15:572-577.
66. Lefkowich JH, Apfelbaum TF: Non-A, non-B hepatitis: Characterization of liver biopsy pathology. J Clin Gastroenterol 1989;11:225-232.
67. Fiore G, Fera G, Napoli N, Vella F, Schiraldi O: Liver steatosis and chronic hepatitis C: A spurious association? Eur J Gastroenterol Hepatol 1996;8:125-129.
68. Lin SC, Shih SC, Kao CR, Chou SY: Prevalence of antibody to hepatitis C virus in patients with nonalcoholic fatty liver. Chung Hua I Hsueh Tsa Chih Taipei 1995;56:80-85.
69. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff ZS, Chapman MJ, Miyamura T, Bréchot C: Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997;94:1200-1205.
70. Soardo G, Pirisi M, Fonda M, Fabris C, Falletti E, Toniutto P, Vitulli D, Cattin L, Gonano F, Bartoli E: Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. J Interferon Cytokine Res 1995;15: 705-712.
71. Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, Ideo G: Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996; 28:436-440.
72. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Host-and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29:198-206.
73. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
74. De Fronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for MDDM. obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
75. Moller DE, Elier JS: Insulin resistance. Mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-948.
76. Ferrannini E: The metabolic syndrome: in Mogensen E (ed): Target Organ Damage in the Mature Hypertensive. London, Science Press, 1993, vol 2, pp 31-49.
77. Godsland IF, Stevenson JC: Insulin resistance: Syndrome or tendency? Lancet 1995;346:100-103.
78. Haffner SM, Miettinen H: Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997;103: 152-162.
79. Ferrannini E, Stern MP: Primary insulin resistance: A risk syndrome: in Leslie RDG, Robbins DC (eds): Diabetes. Clinical Science in Practice. Cambridge, Cambridge University Press, 1995, pp 200-220.
80. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G: Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men. Role of the metabolic syndrome. Thromb Haemost 1996;76:69-73.
81. Perry U, Wannamethee SG, Shaper AG: Prospective study of serum γ-glutamyltransferase and risk of NIDDM. Diabetes Care 1998;21: 732-737.
82. Tacikowski T, Milewski B, Dzieniszewski J, Rakoczy A: Incidence of fatty liver assessed by LISG examination in patients with hyperlipidaemia. Gut 1997;29:A179.
83. Ueno T, Sugawaru H, Sujaku K, Hashimoto O, Tamaki S, Torimura T, Inuzaka S, Sata M, Tanikawa K: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107.
84. Grove J, Daly AK, Bassendine MF, Day CP: Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997;26:143-146.
85. Jovinge S, Hamsten A, Tornvall P, Proudler A, Bavenholm P, Ericsson CG, Godsland I, de Faire U, Nilsson J: Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998;47: 113-118.
86. Nussbaum MS, Fischer JE: Pathogenesis of hepatic steatosis during total parenteral nutrition. Surg Annu 1991;23:1-11.
87. Goto T, Onuma T, Takebe K, Kral JG: The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 1995;19: 841-845.
88. Ibrahim KM, Nicola WG, Salama SH: Mechanism of insulin resistance and hyper-insulinemia in fatty liver. Boll Chim Farm 1996;135:528-540.
89. Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M: The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr 1997;24:317-321.
90. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG: Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995;19:846-850.
91. Eriksson J, Taimela S, Koivisto VA: Exercise and the metabolic syndrome. Diabetologia 1997;40:125-135.
92. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y: Regular physical activity and coronary risk factors in Japanese men. Circulation 1998;97:661-665.
93. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S: The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699-713.
94. Ludwig J, Viggiano TR, McGill DB, Ott BJ: Nonalcoholic steatohepatitis. Mayo Clin Proc 1980;55:434-438.
95. Conte D, Bolzoni P, Fraquelli M, Bodini P, Velio P: Non-alcoholic steatohepatitis. Report of five cases and review of the literature. Ital J Gastroenterol 1995;27:363-365.
96. Baldridge AD, Prez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE: Idiopathic steatohepatitis in childhood: A multicenter retrospective study. J Pediatr 1995;127:700-704.
97. Tarugi P, Lonardo A: Heterozygous familial hypobetalipoproteinemia associated with fatty liver. Am J Gastroenterol 1997;92:1400-1401.
98. Abdelmalek M, Ludwig J, Lindor KD: Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995;20:127-130.
99. Nishina PM, Verstuyft J, Paigen B: Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 1990;31: 859-869.
100. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Ikematsu H, Noguchi A, Tani S, Goto M: Prevalence of gallstone disease in a general population of Okinawa, Japan. Am J Epidemiol 1988;128:598-605.
101. Clain DJ, Lefkowitch H: Fatty liver disease in morbid obesity. Gastroenterol Clin North Am 1987;16:239-252.
102. Braillon A, Capron JP, Hervé MA, Degott C, Quenum C: Liver in obesity. Gut 1985;26: 133-139.
103. Singer P, Honigmann G, Schliack V: Decrease of eicosapentaenoic acid in fatty liver of diabetic subjects. Prostaglandins Med 1980;5: 183-200.
104. Tak PP, ten Kate FJW: Remission of active diabetic hepatitis after correction of hyperglycemia. Liver 1993;13:183-187.
105. Lanza-Jacoby S, Phetteplace H, Tripp R: Enteral feeding a structured lipid emulsion containing fish oil prevents the fatty liver of sepsis. Lipids 1995;30:707-712.
106. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology 1996;23:1464-1467.
107. Keen H: Insulin resistance and the prevention of diabetes mellitus. N Engl J Med 1994;331: 1226-1227.
108. Saltiel AR, Olefski JM: Thiazolinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-1665.
109. Antonucci T, McLain R, Whitcomb R, Lockwood D: Impaired glucose tolerance is normalized by treatment with thiazolidinedione troglitazone. Diabetes Care 1997;20:188-193.
110. Petrie J, Small M, Connell J: Glitazones, a prospect for non-insulin-dependent diabetes. Lancet 1997;349:70-71.
111. Moirand R, Mortaji AM, Loréal O, Paillard L, Brissot P, Deugnier Y: A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-97.
112. Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, Soler J: Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998;21:62-68.
113. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR: Measurement of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113.
114. Hayashi S, Masuda H, Shigematsu M: Liver metastasis rare in colorectal cancer patients with fatty liver. Hepatogastroenterology 1997; 44:1069-1075.
115. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
116. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Shervin R, Shih J, Stamler J, Wentworth D: Multiple Risk Intervention Trial Research Group. Serum cholesterol levels and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992;152:1490-1500.
117. Iso H, Naito Y, Kitamura A, Sato S, Kiyama M, Takayama Y, lida M, Shimamoto T, Sankai T, Komachi Y: Serum total cholesterol and mortality in a Japanese population. J Clin Epidemiol 1994;47:961-969.
118. Lewis B, Tikkanen MJ: Low blood cholesterol and mortality: Causality, consequence and confounders. Am J Cardiol 1994;73:80-85.
119. Epstein FH: Relationship between low cholesterol and disease. Ann NY Acad Sci 1995;748: 482-490.